200 related articles for article (PubMed ID: 26889743)
1. Treatment of ichthyosis and hypernatremia in a patient with Netherton syndrome with a SPINK5 c.153delT mutation using kallikrein inhibiting ointment.
Tiryakioğlu NO; Önal Z; Saygili SK; Önal H; Ersoy Tunali N
Int J Dermatol; 2017 Jan; 56(1):106-108. PubMed ID: 26889743
[No Abstract] [Full Text] [Related]
2. New mutation leading to the full variety of typical features of the Netherton syndrome.
Kogut M; Salz M; Hadaschik EN; Kohlhase J; Hartmann M
J Dtsch Dermatol Ges; 2015 Jul; 13(7):691-3. PubMed ID: 26031502
[No Abstract] [Full Text] [Related]
3. Ichthyosis Linearis Circumflexa as the Only Clinical Manifestation of Netherton Syndrome.
Guerra L; Fortugno P; Pedicelli C; Mazzanti C; Proto V; Zambruno G; Castiglia D
Acta Derm Venereol; 2015 Jul; 95(6):720-4. PubMed ID: 25710899
[TBL] [Abstract][Full Text] [Related]
4. New homozygous SPINK5 mutation, p.Gln333X, in a Turkish pedigree with Netherton syndrome.
Fong K; Akdeniz S; Isi H; Taskesen M; McGrath JA; Lai-Cheong JE
Clin Exp Dermatol; 2011 Jun; 36(4):412-5. PubMed ID: 21564178
[TBL] [Abstract][Full Text] [Related]
5. A new SPINK5 mutation in a patient with Netherton syndrome: a case report.
Alpigiani MG; Salvati P; Schiaffino MC; Occella C; Castiglia D; Covaciu C; Lorini R
Pediatr Dermatol; 2012; 29(4):521-2. PubMed ID: 21692842
[TBL] [Abstract][Full Text] [Related]
6. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
7. Lethal Netherton syndrome due to homozygous p.Arg371X mutation in SPINK5.
Diociaiuti A; Castiglia D; Fortugno P; Bartuli A; Pascucci M; Zambruno G; El Hachem M
Pediatr Dermatol; 2013; 30(4):e65-7. PubMed ID: 23331056
[TBL] [Abstract][Full Text] [Related]
8. [A lethal variant of Netherton syndrome in a large inbred family].
Capri Y; Vanlieferinghen P; Boeuf B; Dechelotte P; Hovnanian A; Lecomte B
Arch Pediatr; 2011 Mar; 18(3):294-8. PubMed ID: 21255986
[TBL] [Abstract][Full Text] [Related]
9. A new SPINK5 donor splice site mutation in siblings with Netherton syndrome.
Tüysüz B; Ojalvo D; Mat C; Zambruno G; Covaciu C; Castiglia D; D'Alessio M
Acta Derm Venereol; 2010; 90(1):95-6. PubMed ID: 20107740
[No Abstract] [Full Text] [Related]
10. A novel SPINK5 mutation and successful subcutaneous immunoglobulin replacement therapy in a child with Netherton syndrome.
Zelieskova M; Banovcin P; Kozar M; Kozarova A; Nudzajova Z; Jesenak M
Pediatr Dermatol; 2020 Nov; 37(6):1202-1204. PubMed ID: 32767583
[TBL] [Abstract][Full Text] [Related]
11. Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation.
Hannula-Jouppi K; Laasanen SL; Ilander M; Furio L; Tuomiranta M; Marttila R; Jeskanen L; Häyry V; Kanerva M; Kivirikko S; Tuomi ML; Heikkilä H; Mustjoki S; Hovnanian A; Ranki A
JAMA Dermatol; 2016 Apr; 152(4):435-42. PubMed ID: 26865388
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of a series of Israeli families with Comèl-Netherton syndrome.
Israeli S; Sarig O; Garty BZ; Indelman M; Bergman R; Sprecher E; Goldberg I
Dermatology; 2014; 228(2):183-8. PubMed ID: 24577329
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of interleukin-33 in the epidermis of two Japanese patients with Netherton syndrome.
Konishi T; Tsuda T; Sakaguchi Y; Imai Y; Ito T; Hirota S; Yamanishi K
J Dermatol; 2014 Mar; 41(3):258-61. PubMed ID: 24506793
[TBL] [Abstract][Full Text] [Related]
14. Severe lethal phenotype of a Japanese case of Netherton syndrome with homozygous founder mutations of SPINK5 c.375_376delAT.
Itoh K; Kako T; Suzuki N; Sakurai N; Sugiyama K; Yamanishi K
J Dermatol; 2015 Dec; 42(12):1212-4. PubMed ID: 26365906
[No Abstract] [Full Text] [Related]
15. Exocrine pancreatic insufficiency in a child with Netherton syndrome.
Machet P; Bodemer C; Lorette G; Fraitag S; Raynaud M; Willot S; Maruani A
Eur J Dermatol; 2016 Jun; 26(3):311-2. PubMed ID: 26986028
[No Abstract] [Full Text] [Related]
16. Netherton Syndrome: A Genotype-Phenotype Review.
Sarri CA; Roussaki-Schulze A; Vasilopoulos Y; Zafiriou E; Patsatsi A; Stamatis C; Gidarokosta P; Sotiriadis D; Sarafidou T; Mamuris Z
Mol Diagn Ther; 2017 Apr; 21(2):137-152. PubMed ID: 27905021
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of Netherton syndrome with dupilumab: A case report and review of the literature.
Wang J; Yu L; Zhang S; Wang C; Li Z; Li M; Zhang S
J Dermatol; 2022 Jan; 49(1):165-167. PubMed ID: 34862657
[TBL] [Abstract][Full Text] [Related]
18. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
Walker AL; Bingham RP; Edgar EV; Ferrie A; Holmes DS; Liddle J; Polyakova O; Rella M; Smith KJ; Thorpe JH; Wang Y; White GV; Young RJ; Hovnanian A
Bioorg Med Chem Lett; 2019 Jun; 29(12):1454-1458. PubMed ID: 31005442
[TBL] [Abstract][Full Text] [Related]
19. Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutations.
Lacroix M; Lacaze-Buzy L; Furio L; Tron E; Valari M; Van der Wier G; Bodemer C; Bygum A; Bursztejn AC; Gaitanis G; Paradisi M; Stratigos A; Weibel L; Deraison C; Hovnanian A
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):575-82. PubMed ID: 22089833
[TBL] [Abstract][Full Text] [Related]
20. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome.
Murase C; Takeichi T; Taki T; Yoshikawa T; Suzuki A; Ogi T; Suga Y; Akiyama M
J Dermatol Sci; 2021 May; 102(2):126-129. PubMed ID: 33773888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
